JP2011510028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011510028A5 JP2011510028A5 JP2010543386A JP2010543386A JP2011510028A5 JP 2011510028 A5 JP2011510028 A5 JP 2011510028A5 JP 2010543386 A JP2010543386 A JP 2010543386A JP 2010543386 A JP2010543386 A JP 2010543386A JP 2011510028 A5 JP2011510028 A5 JP 2011510028A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- atoms
- tautomer
- stereoisomer
- pharmaceutically usable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 19
- 239000000203 mixture Substances 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000006239 protecting group Chemical group 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 239000002834 estrogen receptor modulator Substances 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 2
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000005493 quinolyl group Chemical group 0.000 claims 2
- 229940075993 receptor modulator Drugs 0.000 claims 2
- 102000027483 retinoid hormone receptors Human genes 0.000 claims 2
- 108091008679 retinoid hormone receptors Proteins 0.000 claims 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 2
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 239000003558 transferase inhibitor Substances 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- -1 1 -substituted guanidine Chemical class 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000002229 urogenital system Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008005493.3 | 2008-01-22 | ||
| DE102008005493A DE102008005493A1 (de) | 2008-01-22 | 2008-01-22 | 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate |
| PCT/EP2008/011098 WO2009092431A1 (de) | 2008-01-22 | 2008-12-23 | 4-(pyrrolo[2,3-c]pyridine-3-yl)-pyrimidin-2-amin-derivative |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011510028A JP2011510028A (ja) | 2011-03-31 |
| JP2011510028A5 true JP2011510028A5 (enExample) | 2012-02-16 |
| JP5524864B2 JP5524864B2 (ja) | 2014-06-18 |
Family
ID=40386204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010543386A Expired - Fee Related JP5524864B2 (ja) | 2008-01-22 | 2008-12-23 | ４−（ピロロ［２，３−ｃ］ピリジン−３−イル）ピリミジン−２−アミン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20100292262A1 (enExample) |
| EP (1) | EP2231664A1 (enExample) |
| JP (1) | JP5524864B2 (enExample) |
| KR (1) | KR20100112626A (enExample) |
| CN (1) | CN101918404A (enExample) |
| AR (1) | AR070212A1 (enExample) |
| AU (1) | AU2008348816B2 (enExample) |
| BR (1) | BRPI0821936A2 (enExample) |
| CA (1) | CA2712612A1 (enExample) |
| DE (1) | DE102008005493A1 (enExample) |
| IL (1) | IL206905A0 (enExample) |
| MX (1) | MX2010007927A (enExample) |
| WO (1) | WO2009092431A1 (enExample) |
| ZA (1) | ZA201005959B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101723936B (zh) * | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
| WO2012160464A1 (en) | 2011-05-26 | 2012-11-29 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
| JP6412503B2 (ja) | 2012-11-21 | 2018-10-24 | ピーティーシー セラピューティクス， インコーポレイテッド | 置換逆ピリミジンＢｍｉ−１阻害剤 |
| TWI663166B (zh) | 2013-04-24 | 2019-06-21 | 健生藥品公司 | 新化合物 |
| KR102232595B1 (ko) | 2013-08-30 | 2021-03-26 | 피티씨 테라퓨틱스, 인크. | 치환된 피리미딘 bmi-1 저해제 |
| TWI627173B (zh) | 2013-09-26 | 2018-06-21 | 比利時商健生藥品公司 | 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物 |
| TWI704146B (zh) | 2013-09-26 | 2020-09-11 | 比利時商健生藥品公司 | 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物 |
| EP3071553A4 (en) | 2013-11-21 | 2017-08-02 | PTC Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
| MX371151B (es) | 2014-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | NUEVOS DERIVADOS DE TIENOPIRIMIDINA EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK). |
| BR112017007704B1 (pt) | 2014-10-23 | 2023-04-11 | Janssen Pharmaceutica N.V | Derivados de pirazolopirimidina como inibidores de nik, seu uso e composição farmacêutica que os compreende |
| US9981962B2 (en) | 2014-10-23 | 2018-05-29 | Janssen Pharmaceutica Nv | Pyrazole derivatives as NIK inhibitors |
| ES2718557T3 (es) * | 2014-10-23 | 2019-07-02 | Janssen Pharmaceutica Nv | Nuevos compuestos como inhibidores de nik |
| JP2021535198A (ja) | 2018-08-17 | 2021-12-16 | ピーティーシー セラピューティクス， インコーポレイテッド | 膵臓癌を治療する方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| JP2008502687A (ja) * | 2004-06-14 | 2008-01-31 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| US7855205B2 (en) * | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| JP2009513571A (ja) * | 2005-09-30 | 2009-04-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | ヤヌスキナーゼ阻害剤として有用なデアザプリン |
| DE102006012617A1 (de) * | 2006-03-20 | 2007-09-27 | Merck Patent Gmbh | 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
-
2008
- 2008-01-22 DE DE102008005493A patent/DE102008005493A1/de not_active Withdrawn
- 2008-12-23 KR KR1020107018575A patent/KR20100112626A/ko not_active Withdrawn
- 2008-12-23 AU AU2008348816A patent/AU2008348816B2/en not_active Ceased
- 2008-12-23 CN CN200880125171XA patent/CN101918404A/zh active Pending
- 2008-12-23 BR BRPI0821936-2A patent/BRPI0821936A2/pt not_active IP Right Cessation
- 2008-12-23 US US12/863,817 patent/US20100292262A1/en not_active Abandoned
- 2008-12-23 WO PCT/EP2008/011098 patent/WO2009092431A1/de not_active Ceased
- 2008-12-23 EP EP08871371A patent/EP2231664A1/de not_active Withdrawn
- 2008-12-23 JP JP2010543386A patent/JP5524864B2/ja not_active Expired - Fee Related
- 2008-12-23 CA CA2712612A patent/CA2712612A1/en not_active Abandoned
- 2008-12-23 MX MX2010007927A patent/MX2010007927A/es not_active Application Discontinuation
-
2009
- 2009-01-21 AR ARP090100174A patent/AR070212A1/es unknown
-
2010
- 2010-07-08 IL IL206905A patent/IL206905A0/en unknown
- 2010-08-20 ZA ZA2010/05959A patent/ZA201005959B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025160317A5 (enExample) | ||
| JP2023520333A5 (enExample) | ||
| JP2025160318A5 (enExample) | ||
| RU2562232C2 (ru) | Новые аналоги сс-1065 и их конъюгаты | |
| TWI519312B (zh) | 脂肪酸菸鹼酸共軛物及其用途 | |
| JP2018510191A5 (enExample) | ||
| JP2010529051A5 (enExample) | ||
| JP2010532768A5 (enExample) | ||
| JP2010528995A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2020097596A5 (enExample) | ||
| PH12014502531B1 (en) | Benzamine derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| CN1301712C (zh) | 具有治疗学有用性质的吲哚基－3－乙醛酸衍生物 | |
| EP3528803A1 (en) | Compounds and methods to sensitize cancer cells to cisplatin | |
| JP2020508310A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2018516963A5 (enExample) | ||
| JP2015096544A5 (enExample) | ||
| ES2702911T3 (es) | Agente antitumoral que incluye una baja dosis de clorhidrato de irinotecán hidratado | |
| RU2005132408A (ru) | Ингибиторы киназы | |
| JP2015529229A5 (enExample) | ||
| JP2018524304A5 (enExample) | ||
| JP2012505838A5 (enExample) | ||
| JP2007515419A5 (enExample) | ||
| JP2010539082A5 (enExample) |